Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   43974   clinical trials with a EudraCT protocol, of which   7312   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2010-023081-52
    Sponsor's Protocol Code Number:ENGOT-EN2-DGCG
    National Competent Authority:Spain - AEMPS
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2013-06-10
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedSpain - AEMPS
    A.2EudraCT number2010-023081-52
    A.3Full title of the trial
    A phase III Trial of postoperative chemotherapy or no further treatment for patients with node-negative stage I-II intermediate or high risk endometrial cancer.
    Ensayo fase III de quimioterapia posoperatoria frente a ningún tratamiento posterior en pacientes con cáncer de endometrio de riesgo intermedio o alto, en estadios I o II, con ganglios negativos
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A phase III clinical trial for patients with node-negative stage I-II intermediate or high risk endometrial cancer where the patients will be divided into 2 groups; chemotherapy after surgery versus observation only.
    Un ensayo clínico de fase III para pacientes con cáncer endometrial en estadios I y II intermedia o cáncer endometrial de alto riesgo donde los pacientes se dividieron en 2 grupos, la quimioterapia después de la cirugía versus observación solamente.
    A.3.2Name or abbreviated title of the trial where available
    ENGOT-EN2-DGCG EORTC 55102
    ENGOT-EN2-DGCG EORTC 55102
    A.4.1Sponsor's protocol code numberENGOT-EN2-DGCG
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorDanish Gynaecological Cancer Group
    B.1.3.4CountryDenmark
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportDanish Gynaecological Cancer Group
    B.4.2CountryDenmark
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationEuropean Organisation for the Research and Treatment of Cancer
    B.5.2Functional name of contact pointRegulatory Affairs Department
    B.5.3 Address:
    B.5.3.1Street AddressAvenue E. Mounier, 83/11
    B.5.3.2Town/ cityBrussels
    B.5.3.3Post code1200
    B.5.3.4CountryBelgium
    B.5.4Telephone number+32 (0) 2 774 1023
    B.5.5Fax number+32 (0) 2 774 1030
    B.5.6E-mailregulatory@eortc.be
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Concentrate for solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNPACLITAXEL
    D.3.9.1CAS number 33069-62-4
    D.3.9.4EV Substance CodeSUB09583MIG
    D.3.10 Strength
    D.3.10.1Concentration unit ml millilitre(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number6
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Yes
    D.2.1.2Country which granted the Marketing AuthorisationEuropean Union
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous drip use (Noncurrent)
    Intravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNCARBOPLATIN
    D.3.9.1CAS number 41575-94-4
    D.3.9.4EV Substance CodeSUB06614MIG
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Node-negative stage I-II intermediate or high risk endometrial cancer
    cáncer endometrial en estadios I y II, de mediano y alto riesgo
    E.1.1.1Medical condition in easily understood language
    Endometrial cancer
    Cáncer endometrial
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10014738
    E.1.2Term Endometrial cancer stage I
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 16.0
    E.1.2Level PT
    E.1.2Classification code 10014739
    E.1.2Term Endometrial cancer stage II
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To compare overall survival (OS) of patients treated with adjuvant chemotherapy or to observation.

    Patients with medium and high-risk stage I and II endometrial cancers have, despite radical surgery, a rather high risk for progression.

    Combination chemotherapy regimen of paclitaxel-carboplatin is proposed in this study, as this combination is effective and well tolerated.
    comparar la supervivencia global (SG) de los pacientes tratados con quimioterapia adyuvante oa observación la eficacia de la quimioterapia de combinación adyuvante en un ensayo de fase III de asignación aleatoria, en comparación con ningún tratamiento posterior en pacientes de estadios I y II, de mediano y alto riesgo, con ganglios negativos.
    E.2.2Secondary objectives of the trial
    ?Disease Specific Survival (DSS)
    ?Progression-Free Survival (PFS)
    ?Toxicity (both acute and late)
    ?Compliance
    ?Quality of Life (QOL) and symptom control will be assessed using EORTC QLQ-C30 and EORTC-QLQ-EN34
    ?Rate of isolated pelvic relapse
    ?Rate of isolated distant relapse
    ?Rate of mix local and distant relapse
    Supervivencia global ? SG (criterio de valoración primario)

    Supervivencia específica de la enfermedad ? SEE
    Supervivencia libre de enfermedad ? SLP
    Toxicidad
    Cumplimiento
    Calidad de vida
    Índice de recidiva pélvica aislada (central o de pared pélvica)
    Índice de recidiva distante aislada
    Índice de recidiva mixto, local y distante
    E.2.3Trial contains a sub-study Yes
    E.2.3.1Full title, date and version of each sub-study and their related objectives
    Full details in the protocol section 14; TRANSLATIONAL RESEARCH substudies; pages 45-49
    Todos los detalles en la sección 14 del Protocolo; subestudios investigación traslacional, páginas 45-49
    E.3Principal inclusion criteria
    Target Population
    1.Only node-negative patients are eligible: Histological confirmed endometrial carcinoma with no macroscopic remaining tumour after primary surgery and lymph-node negative disease, with one of the following postoperative FIGO 2009 stage and grade:
    a.Stage I grade 3 endometrioid adenocarcinoma
    b.Stage II endometrioid adenocarcinoma
    c.Stage I and II type 2 histology (clear cell, serous, or squamous cell carci-noma, or undifferentiated carcinoma)
    2. Patients with prior therapy:
    a. Patients have undergone hysterectomy (total abdominal hysterectomy (TAH), radical hysterectomy, laparoscopic or robotic hysterectomy) and & bilateral salpingo-oopherectomy (BSO) (or RH) and+ pelvic lymphadenectomy (LNE) within the past 10 weeks.
    b. LNE: minimum 12 pelvic nodes (6 from each side) should be removed. Para-aortic LNE is optional
    c. Omentectomy strongly recommended in type 2 disease (clear cell, serous, squamous cell carcinoma or undifferentiated carcinoma)
    d. Surgery performed within 10 weeks of randomization. If the dates for hys-terectomy and lymph node dissection are different, 10 weeks are counted from the last surgery, and in that case the gap between two surgeries should not exceed 8 weeks.
    3. Other inclusion criteria
    a. Patients must give informed consent according to the rules and regulations of the individual participating centres
    b. Patients have not received any other anticancer therapy other than surgery.
    c. Adjuvant vaginal brachytherapy is not recommended, though permitted in both arms. In chemotherapy arm, VBT timing of VBT should not cause delay in chemotherapy delivery.
    d. Patients must have WHO performance status of 0-2
    e. Patients must have an adequate bone-marrow, renal and hepatic function (WBC ?3.0x109/L, neutrophils ?1.5x109/L, platelets ?100x109/L, total S-bilirubin <2 x upper normal value, ALAT <2.5 x upper normal value, estimated GFR >50 ml/min (measured or calculated according to Cockroft-Gault or Jeliffe). Up to 5% deviation for hematological values and 10% deviation for s-bilirubin and ALAT are tolerated.
    f. Life expectancy of at least 12 weeks
    g. Patients must be fit to receive combination chemotherapy
    h. Patient?s age >18 years
    Población diana
    1. Solo son elegibles las pacientes con ganglios negativos: carcinoma endometrial con confirmación histológica, sin restos de tumor macroscópico tras la cirugía primaria, sin enfermedad en los ganglios linfáticos y con uno de los siguientes estadios y grados FIGO 2009 postoperatorios:
    a. adenocarcinoma endometrioide en estadio I, grado 3;
    b. adenocarcinoma en estadio II;
    c. Estadios I y II, histología tipo 2 (carcinoma de células claras, serosas, de células escamosas o carcinoma no diferenciado).
    Terapia anterior
    2. Las pacientes han sido sometidas a una histerectomía (histerectomía abdominal total, histerectomía radical, histerectomía laparoscópica o robótica) y a una salpingo-ooforectomía bilateral (BSO) y linfadenectomía pélvica (LNE).
    3. LNE: deben extirparse al menos 12 ganglios pélvicos (6 de cada lado). La LNE paraaórtica es opcional.
    4. Se recomienda encarecidamente una omentectomía en carcinoma de células claras, serosas, escamosas o carcinoma no diferenciado
    5. Cirugía realizada dentro de las 10 semanas anteriores a la asignación aleatoria. Si las fechas de la histerectomía y de la disección de ganglios linfáticos son diferentes, se cuentan 10 semanas desde la última cirugía, y en ese caso el lapso entre ambas cirugías no debe ser de más de 8 semanas.
    6. Las pacientes deben dar un consentimiento informado conforme a las normas y reglamentaciones de cada centro participante.
    7. Las pacientes no deben haber recibido otras terapias contra el cáncer salvo la cirugía.
    8. La braquiterapia vaginal adyuvante está permitida en ambas ramas. En la rama de quimioterapia, la BTV no debe retrasar el calendario de quimioterapia.
    9. Las pacientes deben tener un estado funcional de la OMS de entre 0 y 2.
    10. Las pacientes deben tener una función medular, renal y hepática adecuada (recuento de glóbulos blancos ?3,0x109/l, neutrófilos ?1,5x109/l, plaquetas ?100x109/l, bilirrubina total en suero <2 veces el valor normal superior, ALT <2,5 es el valor normal superior, IFG estimado >50 ml/min. (medido o calculado según Cockroft-Gault o Jeliffe). Se toleran hasta un 5% de desviación de valores hematológicos y un 10% de desviación para bilirrubina en suero y ALT.
    11. Esperanza de vida de al menos 12 meses.
    12. Las pacientes deben estar preparadas para recibir quimioterapia de combinación.
    13. Las pacientes deben tener >18 años de edad.
    E.4Principal exclusion criteria
    1. Target disease exclusions:
    ?Carcinosarcoma, Sarcomas or small cell carcinoma with neuroendocrine differen-tiation.
    2. Prohibited Treatments and/or Therapies
    ?External Beam Radiotherapy
    ?Concurrent cancer therapy
    ?Concurrent treatment with an anticancer investigational agent or participation in another anticancer clinical trial
    3. Other exclusion criteria
    ?Previous or concurrent malignant disease except for curatively treated carcinoma in situ of the cervix or basal cell carcinoma of the skin
    ?Active infection or other serious underlying medical condition, which might prevent the patient from receiving treatment or to be followed
    ?Whatever reasons which interferes with an adequate follow-up
    Excepciones de enfermedad diana
    1. Carcinosarcoma, sarcomas o carcinoma de células pequeñas con diferenciación neuroendocrina.
    Tratamientos y/o terapias prohibidas
    2. Radioterapia de haz externo.
    3. Terapia oncológica simultánea.
    4. Tratamiento simultáneo con un agente anticanceroso experimental o participación en otro ensayo clínico anticanceroso.
    Otros criterios de exclusión
    5. Enfermedad maligna anterior o simultánea, salvo casos de carcinoma in situ de cuello de útero o carcinoma de células basales de la piel tratados con intención curativa.
    6. Infección activa u otra afección médica grave subyacente que pudiera impedir que la paciente recibiera tratamiento o someterse a seguimiento.
    7. Cualquier razón que interfiera con un seguimiento adecuado.
    E.5 End points
    E.5.1Primary end point(s)
    The primary endpoint of this trial is overall survival.
    supervivencia global (SG)
    E.5.1.1Timepoint(s) of evaluation of this end point
    Survival is calculated from the date of randomization until the date of death.
    La supervivencia se calculó a partir de la fecha de la aleatorización hasta la fecha de la muerte.
    E.5.2Secondary end point(s)
    ? Disease Specific Survival (DSS)
    ? Progression-Free Survival (PFS)
    ? Toxicity (both acute and late)
    ? Compliance
    ? Quality of Life (QOL)
    ? Rate of isolated pelvic relapse (central or pelvic wall)
    ? Rate of isolated distant relapse
    ? Rate of mix local and distant relapse
    Supervivencia global ? SG (criterio de valoración primario)

    Supervivencia específica de la enfermedad ? SEE
    Supervivencia libre de enfermedad ? SLP
    Toxicidad
    Cumplimiento
    Calidad de vida
    Índice de recidiva pélvica aislada (central o de pared pélvica)
    Índice de recidiva distante aislada
    Índice de recidiva mixto, local y distante
    E.5.2.1Timepoint(s) of evaluation of this end point
    Survival is calculated from the date of randomization until the date of death.
    The DSS is calculated from the date of randomization until the date of death caused by cancer, Patients who die of non-disease-related causes are censored at time of death.
    The PFS is calculated as time elapsed from date of randomization to date of progression or death of disease, whichever is the first registered event. Vaginal, pelvic and distant relapses will be registered.
    QoL will be registered during whole study period.
    Toxicity will be graded according to the Common Terminology for Adverse Events (CTCAE v4.0)
    La supervivencia se calculó a partir de la fecha de la aleatorización hasta la fecha de la muerte.
    El DSS se calcula a partir de la fecha de la aleatorización hasta la fecha de la muerte causada por el cáncer, los pacientes que mueren de causas no relacionadas con la enfermedad son censurados en el momento de la muerte.
    El PFS se calcula como el tiempo transcurrido desde la fecha de la aleatorización hasta la fecha de la progresión de la enfermedad o la muerte, el que sea el primer evento registrado. Se registrarán recaídas vaginales, pélvica y distante.
    La calidad de vida se registró durante el período de estudio conjunto.
    Toxicidad será calificado de acuerdo con la terminología común para Eventos Adversos (CTCAE v4.0)
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group Yes
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Observation
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned3
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA46
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Austria
    Belgium
    Denmark
    France
    Germany
    Italy
    Netherlands
    Poland
    Portugal
    Spain
    Switzerland
    United Kingdom
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    It is expected to include 678 patients in 3-4 years period and have overall survival available by another 3-4 years
    Se espera incluir 678 pacientes en período de 3-4 años y tienen una supervivencia global a disposición por otros 3-4 años
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years8
    E.8.9.1In the Member State concerned months
    E.8.9.1In the Member State concerned days
    E.8.9.2In all countries concerned by the trial years8
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero Information not present in EudraCT
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) Information not present in EudraCT
    F.1.1.3Newborns (0-27 days) Information not present in EudraCT
    F.1.1.4Infants and toddlers (28 days-23 months) Information not present in EudraCT
    F.1.1.5Children (2-11years) Information not present in EudraCT
    F.1.1.6Adolescents (12-17 years) Information not present in EudraCT
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 510
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 168
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male No
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state40
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 600
    F.4.2.2In the whole clinical trial 678
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Upon the discretion of treating physician.
    A la discreción del médico tratante.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation BGOG
    G.4.3.4Network Country Belgium
    G.4 Investigator Network to be involved in the Trial: 2
    G.4.1Name of Organisation EORTC
    G.4.3.4Network Country Belgium
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2013-08-02
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2013-07-17
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA